Among the DM group, 13 were treated without hypoglycemic medication; the remainder were treated with a dipeptidyl peptidase 4 (DPP-4) inhibitor (n = 2), a biguanide (n = 1), a glucagon-like peptide-1 receptor agonist (n = 1), a combination of sulfonylurea and a biguanide (n = 1), a combination of a DPP-4 inhibitor and a biguanide (n = 1), or a triple-drug combination of sulfonylurea, a biguanide, and a DPP-4 inhibitor (n = 1). The gene discussed is DPP4; the disease is diabetes mellitus.